Downregulation of ESRP2 Promotes Breast Cancer Cell Migration by Activating EMT Transcription Program Through Modulation of ENAH Variable Splicing
Molecular Carcinogenesis · 2026
DOI: 10.1002/mc.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2026. Verfasst von Yuting Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Cell Movement, Breast Neoplasms, RNA-Binding Proteins. Die Arbeit nennt 28 Literaturangaben. Gefördert von: 2024 Guangdong Provincial universities characteristic innovation project, 2025 Annual Guangzhou City University-Institute-Enterprise Jointly Funded Project (Basic and Applied Basic Research Project).
Abstract (Originalsprache)
Epithelial splicing regulatory protein 2 (ESRP2) is a splicing regulator specific to epithelial cell types. Multiple studies have found that its expression is abnormal in various tumors, influencing their occurrence, development, or prognosis. Our previous research indicated that down‐regulating ESRP2 can suppress the proliferation of breast cancer (BC) cells, specifically the MCF‐7 line. To delve deeper into the role of ESRP2 in BC cells, we investigated its impact on the migration of BC cells in vitro and the underlying molecular mechanisms. The outcomes of the in vitro scratch assay and Transwell assay initially confirmed that ESRP2 hinders the migration of both MCF‐7 and MDA‐MB‐231 cells, and that reducing ESRP2 expression enhances their migratory capacity. We demonstrated that the down‐regulation of ESRP2 can boost the migration ability of MCF‐7 cells, and increase the mRNA expression of epithelial‐mesenchymal transition (EMT) transcription factor ZEB2 and related markers N‐cadherin and Vimentin. This suggests that ESRP2 plays a potential regulatory role in inhibiting EMT transcription program. Additionally, results from RNA sequencing and agarose electrophoresis gel experiments predict that down‐regulating ESRP2 may promote exon skipping of the ENAH gene by modulating the alternative splicing of genes associated with cell migration, driving the shift of MCF‐7 cells from an epithelial to a mesenchymal phenotype. Our research reveals a novel mechanism by which ESRP2 affects BC metastasis through post‐transcriptional regulation. ESRP2 may present as a promising biomarker in combating BC cell migration by targeting EMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, Guangdong, China.
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Pharmacy, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Yuting Chen
Förderung
- 2024 Guangdong Provincial universities characteristic innovation project
- 2025 Annual Guangzhou City University-Institute-Enterprise Jointly Funded Project (Basic and Applied Basic Research Project)
Zitieren
APA
Chen, Y., Feng, H., Zhao, C., Huang, L., Liao, Z., Chen, W., Zou, J., & Zhang, S. (2026). Downregulation of ESRP2 Promotes Breast Cancer Cell Migration by Activating EMT Transcription Program Through Modulation of ENAH Variable Splicing. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70093
Vancouver
Chen Y, Feng H, Zhao C, Huang L, Liao Z, Chen W, et al. Downregulation of ESRP2 Promotes Breast Cancer Cell Migration by Activating EMT Transcription Program Through Modulation of ENAH Variable Splicing. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70093
BibTeX
@article{Chen2026,
author = {Chen, Yuting and Feng, Huancun and Zhao, Chengkuan and Huang, Linting and Liao, Zirou and Chen, Wang and Zou, Jian and Zhang, Shuyao},
title = {Downregulation of ESRP2 Promotes Breast Cancer Cell Migration by Activating EMT Transcription Program Through Modulation of ENAH Variable Splicing},
journal = {Molecular Carcinogenesis},
year = {2026},
doi = {10.1002/mc.70093}
}
EUVIMED